Wound Care Innovations: Cellular Therapies, Topical Oxygen, Enzymatic Debridement, and New Dressings

Conclusions

• Head-to-head randomized evidence in diabetic foot ulcers did not show a meaningful healing advantage for cellular over acellular products or over standard care, so product choice should be guided by evidence, patient factors, and cost rather than assumptions.
• Ulcerative hidradenitis suppurativa may represent a distinct ulcerative phenotype separate from PG-like HS, and in the presented experience it seemed to require surgical excision rather than medications alone.
• Topical oxygen therapy appears to improve wound healing in some chronic ulcers and may also reduce pain and analgesic use, although more data are still needed across wound types.
• Bromelain-based enzymatic debridement can achieve rapid and effective debridement in venous leg ulcers and appears superior to collagenase in the limited comparative data presented.
• Intermittent pneumatic compression may have a role in no-option critical limb ischemia for pain relief and possibly wound healing, but the evidence remains insufficient for firm conclusions.
• Medical adhesive-related skin injury is a real and common problem, and light-activated dressings may help reduce skin damage by allowing lower adhesive force at removal.
• A shelf-stable amniotic membrane allograft showed no overall statistically significant benefit for venous leg ulcers, but larger wounds may derive more benefit, suggesting wound size matters in selecting patients.
• Across multiple wound therapies, initial wound size and wound duration remain major predictors of healing outcome.
• The giraffe example was used to support the idea that greater collagen-rich skin thickness may protect against ulcer formation, hinting at collagen-related strategies for recurrence prevention.